News

THANKS FOR THE BIOMAPS PROJECT

150 150 marketing

We thank ICEX España Exportación e Inversiones and the European Regional Development Fund for their support in our project BIOMAPs: Research on new industrial applications of Artennua® and identification and development of new biostimulants.

The results of our research in 2020 on Artennua® derivatives in industrial applications such as biocides, food preservatives and flavorings were profitable and with excellent results.

In addition to having been part of the optimization of different MAPs thanks to the application of our technology ᴛʀɪᴄᴏsᴛɪᴍᴜʟᴀɴᴛ™.

BIOVEGEN’S XV MEETING OF PLANT MOLECULAR BIOLOGY

150 150 marketing

Within the framework of the XV Meeting of Plant Molecular Biology organized by the Spanish Technology Platform for Plant Biotechnology BIOVEGEN, the “COMPANY-FINANCING R&D Session” will be celebrated. As part of the association we have the honor to be represented by the founder, scientist and CEO of Biotech Tricopharming Research SL, Luis Matías Hernández. The objective of the session will be to present TRICOPHARMING’s experience as a source of innovation, its business development strategy and the advances in the R&D projects carried out and in progress. The session will be carried out this 27th of November via online. 

Here is the preliminary program:

Moderator: Gonzaga Ruiz de Gauna. BIOVEGEN
11:00 h

Innovation companies:

  • DVA IBERIA. Andrés de La Cruz. Director of Crop Protection.
  • MAFA BIOSCIENCE. Hanan El Bakkali. Director of Regulatory Affairs.
  • TRICOPHARMING- Luis Matías Hernández. CEO and Co-Founder.
  • TARAZONA. Sergio Monzón. Director of Innovation and R+D.

Management and financing: 

  • CDTI-Centro Desarrollo Tecnológico Industrial. Carlos Sanchez. Biotechnology and Agrifood Department.
  • AEI-State Research Agency. Mª Ángeles Ferre. Thematic Scientific-Technical Programs.
  • BIOVEGEN-Technological Platform of Plant Biotechnology. Gonzaga Ruiz de Gauna. Coordinator.

WE ARE A NEW SEFIT CORPORATE PARTNER

150 150 marketing

We are pleased to announce that from this month we are a corporate partner of the Spanish Society of Phytotherapy SEFIT, which brings together professionals from various fields working in the study and the therapeutic application of medicinal plants.

Being part of SEFIT helps us to promote our research and spread our work with medicinal and aromatic plants (MAPs) which aims not only to increase the therapeutic potential of various MAPs, but also to research and find new uses and therapeutic applications in order to promote population health.

read more

PROMISING RESULTS WITH OUR TRICOSTIMULANT™ ON BASIL PLANTS

150 150 marketing

From our R&D department we are working to improve the quality and yield on diverse Medicinal & Aromatic plants (MAPs). TricoStimulant™ is a last-generation supplementary plant preparation that combines metabolic engineering and -omics tools especially formulated to enhance MAPs physiological properties.

After the success of TricoStimulant™ with our first product, Artennua®,  we are adapting and personalizing our innovative technology towards other MAPs of special interest as the preliminary results with basil we present today. Basil (Ocimum basilicum) has been used as a medicinal and aromatic plant for centuries. Nowadays it is used in many fields of human activity, especially in the food industry and in gastronomy. It is one of the species of aromatic medicinal plants that has a high content of essential oils, especially eugenol, widely used in medicine. Basil is also important for the pharmaceutical industry and is still used in traditional medicines in many parts of the world due to its anti-inflammatory, antioxidant and antiseptic properties and for treating gastric, respiratory and urinary disorders. 

Our preliminary results are promising and show that we are on the right way, as we observed a very powerful effect significantly increasing both the aerial fresh weight and the number of leaves in basil plants. Indeed, figure 1 shows how different doses of TricoStimulant™ applied exert their beneficial effect on basil plants in hydroponic systems. As shown in the graph we have obtained an increase of 60% in the number of leaves and 55% in shoot fresh weight. As these are powerful preliminary results, our conviction is that we will achieve greater increases in the near future and we are working towards this goal.

To better illustrate the effect of our technology on basil plants, figure 2 shows how applications of increasing doses of TricoStimulant™ correlate with increased growth and development of the plant. We are proud of our TricoStimulant™ and we are convinced that this technology has a promising future to improve therapeutic potential on other MAPs.

Figure 1: Shoot fresh weight, leaves numbers , are shown after the application of different doses of TricoStimulant™ on nutrient and non-nutrient substrates.

Figure 2: The results onshoot fresh weight and leaves number of the application of increasing doses of TricoStimulant™ applied to plants grown in soil substrate are shown from left to right.

MEDICINAL AND AROMATIC PLANTS TO FIGHT AGAINST COVID-19

150 150 marketing

We continue working in our research to collaborate with a treatment for the COVID-19.

Watch the CMM Castilla-La Mancha Media interview about our work with Artemisia annua and its possible application in the fight against the virus.

read more

TRICOPHARMING, A LEADING COMPANY THAT ANTICIPATE TOMORROW

150 150 marketing

Our company Tricopharming was included by the ABC newspaper in the top of the biotechnology and ICT companies that are committed to development and innovation in Spain thanks to our biotechnology based on biopharmaceutical agriculture and our first success case Artennua®, a optimized version of Artemisia annua.

read more

THE IMPULSE OF ACCIÓ AND THE CATALONIA REGION TO TRICOPHARMING – STARTUP CAPITAL 2019

150 150 marketing
Startup Capital 2019

 

Glad to announce that Tricopharming has been selected among the 20 most innovative tech startups of Catalonia Region within the framework of the Startup Capital 2019 call!

Startup Capital boosts early stage technological companies helping to accelerate their product development and road map to market by co-financing business plan implementation. 

The call is addressed to high technological Startups located in Catalonia region. The catalan startup ecosystem is very dynamic according to recent regional statistics showing a growing trend in startup number with a total 1.504 in 2019, meaning a 38% more than 3 years ago. In the previous editions of the call, selected StartUp were all standing out for their technological and innovation impact.

Time frame is 18 months, starting in November 2019. The initiative consists in a direct grant of up to 75.000 euros for recently-created technological startups, plus a mentoring program carried out by ACCIO via mentorship specialists and major representatives of the technology, health and biotech industry. The initiative finances measures to implement the business plan and to accelerate access to early stage financing rounds.

Thanks to the project we will be able to conduct on-field beta testing to eventually launch on the market our new business line by the end of 2020. 

On the other side, thanks to Startup Capital financing, we will be able to scale up faster the production and commercialization of our product Artennua®, since 2019 available in the two formats capsules and B2B bags.

That’s a very good news for us! It joins the good results achieved in 2019: at the beginning of 2019 we took part to the Barcelona Activa pre-Acceleration Program – being to date incubated in the MediaTic Tech StartUps @22 district hub, we received the Cervera project co-funding by CDTI for our R&D activity and last but not least, the ‘Seal of Excellence’ by the European Commission in the framework of the SME Instrument phase 1 call.

A BIOCHEMIST FROM CUENCA, IN SEARCH OF A TREATMENT FOR COVID-19

150 150 marketing

Luis Matías, through his company Biotech Tricopharming Research, wants to study the antiviral properties of his product derived from Artemisia annua with the new coronavirus

read more

TRICOPHARMING ON RADIO TELEVISION CANARIA RTVC

150 150 marketing

Artemisia annua plant contains more than 400 metabolites. Among them, stands out the molecule artemisinin, the most effective antimalarial treatment to date. Could Artemisia annua and/or artemisinin molecule be a good candidate to fight Covid-19? This TV news contributes to the debate with our CEO Luís Matías Hernández, PhD, and our Agricultural Engineer Andrés Acosta Pérez by Biotech Tricopharming Research.

Watch the journalistic note of the newscast Telenoticias 1 of Radio Televisión Canaria RTVC.

A NEW PLATFORM FOR MEDICINAL AND AROMATIC PLANTS IS RUNNING THANKS TO CDTI AND OUR CERVERA PROJECT

150 150 marketing
Validation of a biostimulation technology able to increase molecules´ and secondary metabolites concentration both in Artemisia annua plant and other Medicinal and Aromatic Plants.
The project also pretends to test and validate the therapeutic and functional potential of Artennua® extract.

The Centre for the Technological and Industrial Development (CDTI) by Government of Spain, approved our project proposal ‘Validation of a production platform of Biomolecules of Industrial Interest’ presented in the framework of the budgetary line ‘Cervera’. The project, co-funded by EU funds, will last until March 2021 and focuses on different R&D goals. Among them we can find  the validation of a biostimulation technology able to increase molecules´ and secondary metabolites concentration both in Artemisia annua plant and other Medicinal and Aromatic Plants species (Cannabis spp, HypericumCnicus benedictusArtemisia vulgaris, Lavandula). On the other side the project pretends to test and validate the therapeutic and functional potential of our commercial extract Artennua® as food conservative, antioxidant, anti inflammatory, antimicrobian and immune system agent.

Medicinal and Aromatic Plants.

Project execution is being guaranteed thanks to the collaboration with two spanish technologic centres belonging to the national centres of the Ministry of Science, Innovation and University network: CTAEx (Agrifood Technology Institute of Extremadura) who is participating in the development of field trials of experimental crops for the technological validation of the platform for the production of biomolecules, and CNTA (National Centre of Food Technology and Safety of Navarra) for the development of in vitro tests with Artennua® in cell cultures to evaluate the therapeutic potential in different applications. Moreover, they have been working on developing a new concentrated formula of Artennua®.

Thanks to CDTI and our achievement at Cervera project, we have been working on our production platform for biomolecules of Industrial interest. We will continue working on the validation of our biostimulation technology in various species of Medicinal and Aromatic plants (MAPs), as well as we have done with Artemisia annua plant.